Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Gross Profit: 2009-2025

Historic Gross Profit for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to $28.9 million.

  • Gyre Therapeutics' Gross Profit rose 17.96% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.4 million, marking a year-over-year increase of 1.32%. This contributed to the annual value of $101.9 million for FY2024, which is 6.38% down from last year.
  • Gyre Therapeutics' Gross Profit amounted to $28.9 million in Q3 2025, which was up 12.94% from $25.6 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Gross Profit registered a high of $48.1 million during Q4 2022, and its lowest value of -$14,000 during Q4 2021.
  • Its 3-year average for Gross Profit is $26.0 million, with a median of $25.9 million in 2023.
  • Per our database at Business Quant, Gyre Therapeutics' Gross Profit plummeted by 157.14% in 2021 and then surged by 595,250.00% in 2023.
  • Gyre Therapeutics' Gross Profit (Quarterly) stood at -$14,000 in 2021, then spiked by 343,357.14% to $48.1 million in 2022, then slumped by 46.11% to $25.9 million in 2023, then climbed by 3.08% to $26.7 million in 2024, then grew by 17.96% to $28.9 million in 2025.
  • Its Gross Profit stands at $28.9 million for Q3 2025, versus $25.6 million for Q2 2025 and $21.2 million for Q1 2025.